Hershko C, Grady R W, Cerami A
J Lab Clin Med. 1978 Aug;92(2):144-51.
The mechanism of action of two recently identified iron-chelating drugs, RA and CHA, was compared with that of two well-known chelating agents, DF and DTPA, in hypertransfused rats labeled with selective parenchymal and RE cell radioiron probes. The existence of two alternative pathways for the in vivo chelation of iron has been indicated by the present findings. The first of these pathways involves the extracellular chelation of RE cell iron and its subsequent excretion in the urine. The second pathway is concerned with the intracellular binding of hepatic parenchymal cell iron and its subsequent excretion in the bile. Iron chelation by DTPA is restricted to the first pathway, whereas iron chelation by CHA is confined to the second pathway. DF and RA have a dual effect and are able to enhance the urinary excretion of RE cell iron as well as the biliary excretion of hepatic parenchymal iron. Hypertransfused rats are a simple and useful experimental model for the study of iron mobilization by chelating agents of potential clinical usefulness. However, further studies are required to show whether the pathways of iron chelation identified in rats may represent the mechanism of iron chelation in patients with transfusional iron overload.
在使用选择性实质细胞和网状内皮(RE)细胞放射性铁探针标记的多次输血大鼠中,比较了两种最近鉴定出的铁螯合剂RA和CHA与两种知名螯合剂去铁胺(DF)和二乙三胺五乙酸(DTPA)的作用机制。本研究结果表明存在两条体内铁螯合的替代途径。其中第一条途径涉及RE细胞铁的细胞外螯合及其随后经尿液排泄。第二条途径与肝实质细胞铁的细胞内结合及其随后经胆汁排泄有关。DTPA的铁螯合作用仅限于第一条途径,而CHA的铁螯合作用则局限于第二条途径。DF和RA具有双重作用,能够增加RE细胞铁的尿排泄以及肝实质铁的胆汁排泄。多次输血大鼠是研究具有潜在临床用途的螯合剂对铁动员作用的一种简单而有用的实验模型。然而,还需要进一步研究以确定在大鼠中鉴定出的铁螯合途径是否可能代表输血性铁过载患者的铁螯合机制。